Novel and evolving therapies in the treatment of malignant phaeochromocytoma: Experience with the mTOR inhibitor everolimus (RAD001)

Keyphrases

• AKT/mammalian Target of Rapamycin 33%
• Benign Disease 33%
• Benign or Malignant 33%
• Biochemical Markers 33%
• Chemotherapy 33%
• Compassionate Use 33%
• Current Therapies 33%
• Effective Therapy 33%
• Everolimus 100%
• Evolving Therapies 100%
• Histopathological Features 33%
• In Vitro Study 33%
• Malignant Disease 33%
• Malignant Paraganglioma 33%
• Malignant Pheochromocytoma 100%
• Mammalian Target of Rapamycin Pathway 33%
• Mammalian Target of Rapamycin Signaling 33%
• Metastasis 33%
• Molecular Features 33%
• MTOR Inhibitor 100%
• Neuroendocrine Tumor 66%
• Novartis 33%
• Novel Therapies 100%
• Paraganglioma 33%
• Pheochromocytoma 100%
• RAD001 100%
• Radionuclide Therapy 33%
• Response to Treatment 33%
• Success Rate 33%
• Surgery Therapy 33%
• Tumor Bulk 33%

Medicine and Dentistry

• Biochemical Marker 16%
• Compassionate Use 16%
• Disease 16%
• Everolimus 100%
• In Vitro 16%
• Mammalian Target of Rapamycin Inhibitor 100%
• Mechanistic Target of Rapamycin 33%
• Metastatic Carcinoma 16%
• Neoplasm 16%
• Neuroendocrine Tumor 33%
• Paraganglioma 33%
• Pheochromocytoma 100%
• Radionuclide Therapy 16%
• Symptom 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Biochemical Marker 16%
• Chemotherapy 16%
• Disease 16%
• Everolimus 100%
• Mammalian Target of Rapamycin 33%
• Mammalian Target of Rapamycin Inhibitor 100%
• Neoplasm 16%
• Neuroendocrine Tumor 33%
• Paraganglioma 33%
• Pheochromocytoma 100%
• Radioisotope 16%
• Symptom 16%